Mr. Max Schwartz reports

ORGANIGRAM TO REPORT THIRD QUARTER FISCAL 2026 RESULTS ON AUGUST 11, 2026

Organigram Global Inc. will release earnings results for its third quarter ended June 30, 2026, on Tuesday, Aug, 11, 2026, prior to market open.

The company will host a conference call to discuss its results with details as follows.

Date:  Tuesday, Aug. 11, 2026

Time:   8 a.m. Eastern Time

Please register on-line for the conference call.

To ensure you are connected for the full call, the company suggests registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through e-mail, including dial-in details and unique conference call codes for entry. Registration is open through the live call.

For the webcast, participants will receive their details by e-mail.

A replay of the webcast will be available within 24 hours after the conclusion of the call on Organigram's website and will be archived for a period of 90 days following the call.

About Organigram Global Inc.

Organigram is a company (listed on the Nasdaq Global Select Market and Toronto Stock Exchange) whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Sanity Group, Organigram participates in the German medical cannabis market and other emerging markets within Europe.

Organigram is focused on producing high-quality cannabis for adult consumers as well as extending the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Monjour, Tremblant, Collective Project, Trailblazer, Boxhot and Debunk. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, Zoiks, Endosane, Vaay and Grashaus. Organigram operates facilities in Moncton, N.B., and Lac Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario -- one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, postprocessing of minor cannabinoids and infused preroll production. The facility in London will be optimized for labelling, packaging and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.

We seek Safe Harbor.